Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2019 / Cilt: 24 - Sayı: 4

Evaluation of Non-invasive Diagnostic Methods as Indicators of Fibrosis in Patients with Chronic Hepatitis B

Kronik Hepatit B Hastalarında Fibrozis Göstergesi Olan Noninvaziv Tanı Yöntemlerinin Değerlendirilmesi

Pages
272–278
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Introduction: Liver biopsy is recommended before the commencement of antiviral treatment for patients with chronic hepatitis B (CHB).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Liver biopsy is recommended before the commencement of antiviral treatment for patients with chronic hepatitis B (CHB).
📊
Key Findings & Data:The aim of this study was to evaluate the efficacy of several indirect markers of liver fibrosis (APRI, AP, FIB-4, and AST /ALT ratio) in patients with CHB.
💡
Conclusion & Impact:Conclusion: According to the results of our study, FIB-4 score and AP index may be considered as good indicators for predicting advanced fibrosis in CHB subjects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Liver biopsy is recommended before the commencement of antiviral treatment for patients with chronic hepatitis B (CHB). Although liver biopsy is the gold standard procedure, many noninvasive tests have been established for the determining of liver damage. The aim of this study was to evaluate the efficacy of several indirect markers of liver fibrosis (APRI, AP, FIB-4, and AST /ALT ratio) in patients with CHB. Materials and Methods: In total, 91 patients with chronic hepatitis B were included into the study. Then patients with CHB infection were divided as mild and advanced fibrosis, and these two groups were compared. Results: Mean age of the patients was 39.5 ± 14.9 years. The areas under receiver operating characteristic curve in the prediction of significant fibrosis were 0.756, 0.849, 0.742 and 0.825 for APRI, FIB-4, AST/ALT ratio, and AP index, and FIB-4 score and AP index were the best indicators for the detection of advanced fibrosis. For FIB-4 and AP index, the cut-off values for the prediction of advanced fibrosis were ≥ 1.05 and ≥ 3.5 with a sensitivity and specificity of 87%, 74% and 62%, 75% respectively. Conclusion: According to the results of our study, FIB-4 score and AP index may be considered as good indicators for predicting advanced fibrosis in CHB subjects.

Özet

Giriş: Kronik hepatit B (KHB) hastalarında antiviral tedavi başlanmadan önce karaciğer biyopsisinin yapılması önerilmektedir. Biyopsi karaciğer hasarını göstermek için halen altın standart olmakla beraber, bu hasarı belirleyebilmek için birçok noninvaziv testin etkinlikleri denenmektedir. Bu çalışmada KHB hastalarında, karaciğer fibrozisinin çeşitli indirekt göstergelerinin (APRI, AP, FIB-4, AST/ALT oranı) etkinliklerinin değerlendirilmesi amaçlandı. Materyal ve Metod: Kronik hepatit B’li 91 hasta çalışmaya dahil edildi. Kronik hepatit B hastaları fibrozis skoruna göre hafif fibrozis ve ileri fibrozis olanlar olmak üzere iki gruba ayrılarak karşılaştırmalar yapıldı. Bulgular: Ortalama yaş KHB olgularında 39.5 ± 14.9 yıl olarak bulunmuştur. Kronik hepatit B’li olgularda belirgin fibrozisi saptamada APRI, FIB-4, AST/ALT oranı, AP skorları için ROC eğrisi altında kalan alanlar sırasıyla 0.756, 0.849, 0.742 ve 0.825 idi. ROC analizinde, ileri fibrozis en iyi FIB-4 skoru ve AP indeksi ile hesaplanmıştır. FIB-4 skoru ve AP indeksi için ileri fibrozis saptamasının en iyi kesim değerleri ≥ 1.05 ve ≥ 3.5 olarak alındığında; sırasıyla duyarlılık %87 ve %74, özgüllük %62 ve %75 olarak saptanmıştır (p< 0.0001). Sonuç: Çalışmamızın sonuçlarına göre FIB-4 skoru ve AP indeksinin KHB’li hastalarda belirgin fibrozisi tespit etmede iyi bir gösterge olduğu düşünüldü. Ancak bu noninvaziv testlerin değerlendirilmesi için daha geniş çalışmalara ihtiyaç vardır.

🔖

Cite This Article

ATAY, K. (2019). Evaluation of Non-invasive Diagnostic Methods as Indicators of Fibrosis in Patients with Chronic Hepatitis B. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 24 - Sayı: 4, 272–278. https://ajindex.com/articles/161035

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Cengiz T, Kıyan M, Yavaşoğlu O, Şahin Uğurel M, Karahan M, Kılıç H. HBsAg taşıyıcılarının yakın aile çevresindeki bireylerde ELISA ile HBsAg’ın araştırılması. OMÜ Tıp Dergisi 1992;9(2):137-43
  2. Lok ASF, McMahon BJ. AASLD practice guideline: chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-61
  3. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25(Suppl 1):S3-8
  4. Shindo M, Hamada K, Nishioji K, Muramatsu A, Oda Y, Okuno T. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B. J Gastroenterol 2004;39:260-7
  5. Bravo A, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500
  6. Crespo J. The art of predicting fibrosis in hepatitis C. Rev Esp Enf Dig 2006;98:153-60
  7. Mardini H, Record C. Detection of assessment and monitoring of hepatic fibrosis: biochemistry or biopsy. Ann Clin Bio Chem 2005;42:441-7
  8. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68.276 biopsies. J Hepatol 1986; 2:165-73
  9. Bedossa P, Dargere D, Paradşs V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1356-8
  10. Hui AY, Chan HL, Wong VW. Identification of chronic hepatitis B patients without significant fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005;100:616-23
  11. Poynard T, Imbert-Bismut F, Munteanu M. Overview of the diagnostic value of biochemical markers of liver fibrosis and necrosis in patients with chronic hepatitis C. Comp Hepatol 2004;3:8
  12. Zeng M, Lu L, Mao Y. Prediction of significant fibrosis in HBeAg positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005;42:1437-45
  13. Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time. Hepatology 2005;100:19813
  14. Wai CT, Greenson JK, Fontana RJ. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26
  15. Chrysantos NV, Papatheodoritis GV, Savvas S. Aspartate aminotrasferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol 2006;18:389-96
  16. Sterling RK, Lissen E, Clumerk N. Development of a simple noninvazive index to predict significant fibrosis in patients with